GlassScriptPhysician profile
James Taterka
NPI 1528012531
$7,400.45
in general payments reported to CMS, 2019-2025
41 companies · $2,128 in 2025
The $2,128 reported for 2025 was more than what 80% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,187 · 2020: $221 · 2021: $465 · 2022: $1,112 · 2023: $1,102 · 2024: $1,184 · 2025: $2,128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,361 · Education: $53.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,360.88 |
| Education | $53.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,514.39 | 2019-2025 | Linzess, Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $762.99 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Gilead Sciences, INC. | $531.50 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $521.48 | 2019-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $477.22 | 2019-2025 | Entyvio, Eohilia |
| Pfizer INC. | $308.99 | 2019-2025 | |
| Celgene Corporation | $262.45 | 2022-2024 | Zeposia |
| Braintree Laboratories, INC. | $255.84 | 2019-2022 | |
| Madrigal Pharmaceuticals | $133.88 | 2025 | Rezdiffra |
| Ipsen Biopharmaceuticals, INC | $128.14 | 2024-2025 | Iqirvo, Bylvay |
| Celltrion USA INC. | $115.51 | 2024-2025 | Vegzelma, Zymfentra |
| Shionogi INC | $112.70 | 2019-2020 | |
| Aimmune Therapeutics, INC. | $112.23 | 2024-2025 | Zenpep |
| Ferring Pharmaceuticals INC. | $96.26 | 2019-2023 | Rebyota |
| Ironwood Pharmaceuticals, INC | $95.93 | 2020-2023 | Linzess |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Taterka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.